Alembic Pharmaceuticals receives USFDA approval for its generic Dabigatran Etexilate Capsules (110 mg) for deep vein thrombosis and pulmonary embolism prophylaxis.
New Delhi, Aug 13 (PTI) Alembic Pharmaceuticals on Tuesday said it has received approval from the US health regulator to market a generic product indicated for prophylaxis of deep vein thrombosis.
The company has received approval from the US Food and Drug Administration (USFDA) to market Dabigatran Etexilate Capsules (110 mg), the drug firm said in a regulatory filing.
Dabigatran Etexilate Capsules are indicated for prophylaxis of deep vein thrombosis and pulmonary embolism following hip replacement surgery.
The approved product is therapeutically equivalent to Boehringer Ingelheim Pharmaceuticals Inc's Pradaxa Capsules (110 mg).
The company said it now has a cumulative total of 211 ANDA (abbreviated new drug application) approvals from the USFDA.
Shares of the company on Tuesday closed 3.17 per cent down at Rs 1,076 apiece on the BSE.
Rediff.com » Market News » Alembic Gets USFDA Approval for Generic Deep Vein Thrombosis Medication
DISCLAIMER - This article is from a syndicated feed. The original source is responsible for accuracy, views & content ownership. Views expressed may not reflect those of rediff.com India Limited.
© 2024 Rediff.com India Limited. All rights reserved. Disclaimer - Terms of Service - Privacy Policy - Feedback